DRTS Alpha Tau Medical Ltd. Annual reports only
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1871321 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY-34.3%
TTM EPS YoY-17.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-61.0%
ROA-44.4%
ROIC (approx.)-58.7%
Asset turnover—
Leverage & solvency
Liabilities / assets27.0%
Debt / equity0.00x
Current ratio7.45x
Interest coverage-121.87x
Cash quality & payout
Operating cash flow / net income0.63x
Accruals ratio-16.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $32.06M | $27.02M | $26.42M | $20.89M | $11.45M |
| SG&A expense | $8.36M | $6.67M | $7.33M | $10.27M | $1.86M |
| Operating income | -$42.29M | -$36.04M | -$35.68M | -$32.14M | -$13.79M |
| Interest expense | $347,000 | $303,000 | $75,000 | — | — |
| Pretax income | -$42.51M | -$31.74M | -$29.14M | -$33.74M | -$27.26M |
| Income tax | $121,000 | $6,000 | $16,000 | $20,000 | $7,000 |
| Net income | -$42.63M | -$31.75M | -$29.16M | -$33.76M | -$27.27M |
| EBITDA | -$41.06M | -$34.94M | -$34.61M | -$31.16M | -$13.01M |
| EPS (basic) | -0.53 | -0.45 | -0.42 | -0.53 | -0.67 |
| EPS (diluted) | -0.53 | -0.45 | -0.42 | -0.53 | -0.67 |
| Weighted avg. shares (diluted) | 80.58M | 69.93M | 69.38M | 63.53M | 40.53M |
| Balance sheet | |||||
| Cash & equivalents | $12.20M | $13.72M | $12.66M | $6.69M | $23.85M |
| Short-term investments | $60.92M | $45.88M | $69.13M | $98.69M | $8.08M |
| Current assets | $78.30M | $64.23M | $85.76M | $106.48M | $32.64M |
| PP&E, net | $19.66M | $13.93M | $12.80M | $7.47M | $7.55M |
| Total assets | $105.65M | $86.20M | $107.39M | $120.15M | $42.22M |
| Current liabilities | $10.51M | $8.68M | $7.10M | $4.34M | $4.41M |
| Total liabilities | $28.55M | $23.54M | $22.91M | $14.49M | $23.03M |
| Shareholders' equity | $77.10M | $62.67M | $84.47M | $105.66M | -$34.78M |
| Shares outstanding | 88.01M | 70.38M | 69.67M | 69.11M | 40.53M |
| Cash flow statement | |||||
| Operating cash flow | -$26.68M | -$19.78M | -$17.96M | -$23.88M | -$11.81M |
| Capital expenditure | $6.08M | $2.24M | $6.40M | $904,000 | $2.93M |
| Free cash flow | -$32.76M | -$22.02M | -$24.36M | -$24.78M | -$14.74M |
| Investing cash flow | -$20.59M | $20.77M | $18.68M | -$89.94M | $19.27M |
| Financing cash flow | $45.77M | $25,000 | $5.30M | $96.91M | $111,000 |
| Depreciation & amortization | $1.23M | $1.10M | $1.07M | $979,000 | $776,000 |
| Stock-based compensation | $10.62M | $9.92M | $7.93M | $6.75M | $812,000 |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.